Drug intelligence / Profile preview

DA-1241 + sitagliptin

Development stage: Unknown
Lead developer: MetaVia
Modality: Small Molecules
Administration: Oral

Overview

The combination of DA-1241 and sitagliptin is being developed as a potential treatment for Metabolic dysfunction-associated steatohepatitis (MASH), previously known as non-alcoholic steatohepatitis (NASH). DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist that works by activating GPR119 in the gut, leading to the release of GLP-1, GIP, and PYY, which contribute to glucose metabolism, lipid metabolism, and weight loss. When combined with sitagliptin (a DPP-4 inhibitor), the treatment has shown promising results in preclinical studies and is currently being evaluated in clinical trials.

Targets

GPR119 (Glucose-dependent insulinotropic receptor)

Beyond the preview

Go deeper on DA-1241 + sitagliptin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-1241 + sitagliptin.

Explore the full profile